Nxera Pharma Co (Nxera Pharma Co) Change In Receivables : $12.2 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co Change In Receivables?

Nxera Pharma Co's change in receivables for the quarter that ended in Mar. 2024 was $13.0 Mil. It means Nxera Pharma Co's Accounts Receivable declined by $13.0 Mil from Dec. 2023 to Mar. 2024 .

Nxera Pharma Co's change in receivables for the fiscal year that ended in Dec. 2023 was $9.1 Mil. It means Nxera Pharma Co's Accounts Receivable declined by $9.1 Mil from Dec. 2022 to Dec. 2023 .

Nxera Pharma Co's Accounts Receivable for the quarter that ended in Mar. 2024 was $29.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Nxera Pharma Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 87.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nxera Pharma Co's liquidation value for the three months ended in Mar. 2024 was $-237.2 Mil.

Nxera Pharma Co Change In Receivables Historical Data

The historical data trend for Nxera Pharma Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Change In Receivables Chart

Nxera Pharma Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-8.46

7.25

-7.02

-1.56

9.13

Nxera Pharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															10.56	2.24	4.88	-7.88	12.97

Nxera Pharma Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.2 Mil.

Nxera Pharma Co (OTCPK:SOLTF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nxera Pharma Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	29.396	/	30.777	*	91
=	87.16

2. In Ben Graham's calculation of liquidation value, Nxera Pharma Co's accounts receivable are only considered to be worth 75% of book value:

Nxera Pharma Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	310.475	-	576.731	+	0.75 * 29.396	+	0.5 * 13.924
=	-237.2

Nxera Pharma Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co (Nxera Pharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

4565:Japan JSS:Germany

Address

2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083

Website

http://www.sosei.com

Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.